Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

TNGX 11.27.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-12-05
Name of Upcoming Event:Piper Sandler 36th Annual Healthcare Conference
Full Press ReleaseSEC FilingsOur TNGX Tweets

About Gravity Analytica

Recent News

  • 12.05.2024 - Piper Sandler 36th Annual Healthcare Conference
  • 12.03.2024 - Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 11.27.2024 - Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.02.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
PDF Version

BOSTON--(BUSINESS WIRE)--Nov. 27, 2024--Tango Therapeutics, Inc.(NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced thatAdam Crystal, M.D., Ph.D., President, Research & Development ofTango Therapeutics, is scheduled to present at the Piper Sandler 36thAnnual Healthcare Conference onThursday, December 5, 2024at1:30 PM ET.

A live webcast of the presentation will be available under the "Events & Presentations" tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

AboutTango Therapeutics

Tango Therapeuticsis a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visitwww.tangotx.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241127715588/en/

Investor Contact:Sam Martin/Andrew VulisArgot Partnerstango@argotpartners.comMedia Contact:Amanda Brown GalgaySVP, Corporate Communications,Tango Therapeuticsmedia@tangotx.com

Source:Tango Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com